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ABSTRACT
THE EFFECT OF EXERCISE AND CALORIC RESTRICTION ON
CARDIAC NF-kB SIGNALING AND INFLAMMATION IN OTSUKA
LONG-EVANS TOKUSHIMA FATTY (OLETF) RATS
SEPTEMBER 2015
ANGEL EXPEDITO BAEZ, B.S., UNIVERSITY OF MASSACHUSETTS
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed By: Professor Sarah Witkowski

Introduction: Cardiometabolic syndrome is considered a chronic low-grade
inflammatory condition that affects various organs and tissues. Individuals with type 2
diabetes mellitus (T2DM) and obesity are at an increased risk for developing the
cardiometabolic syndrome and have greater rates of cardiovascular disease (CVD).
These conditions are also associated with increased systemic and local inflammation and
greater expression of pro-inflammatory markers such as monocyte chemoattractant
protein 1 (MCP-1), tumor necrosis factor-α (TNF-α), and interleukin 1β (IL-1β) in many
tissues. The heart is adversely affected by the inflammation and metabolic changes
induced by diabetes and obesity. Nuclear transcription factor kappa B (NF-κB) activity is
known to be related to inflammation and cytokine production. However, there is limited
information on whether NF-κB signaling and inflammation play a role in early cardiac
pathogenesis related to obesity and diabetes and whether lifestyle changes known to
prevent or treat these diseases are effective in the heart. Purpose: Therefore, the purpose
of this study was to compare the effect of exercise (EX) and caloric restriction (CR) to
alter NF-κB signaling, inflammation, and markers of cardiac dysfunction in the heart of
iii

20-week old Otsuka Long Evans Tokushima (OLETF) rats. Methods: Hearts of male 20
week old OLETF rats from a previous study (Crissey et al., 2014) were collected for gene
expression (RT-PCR), NF-κB activity, and markers of inflammation and immune cell
infiltration. Results: There were no significant differences detected in markers of cardiac
dysfunction including, α-MHC, β-MHC, ANP, BNP, COL1, COL3 (all p>0.05). Second,
1-way ANOVA showed that there was trend for an overall effect of group (p=0.07) on
NF-κB activation where CR tended to be greater compared to SED and WR (p=0.06).
Finally, there were no significant differences between groups in inflammatory and
immune cell markers; CD4, F4/80, CD68, IL-1β, MCP-1, TGFB1, and TNF-α (all
p>0.05). Conclusion: This study shows that at 20 weeks, a time when OLETF animals
exhibit characteristics of the metabolic syndrome such as hypertension, mild obesity, and
increased insulin resistance, EX and CR do not reduce markers of cardiac dysfunction
and inflammation, potentially because inflammation does not influence the heart at this
early time period in the development of the disease. Further, the trend of greater NF-κB
activity in CR compared to EX and SED, needs further exploration.
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CHAPTER 1
INTRODUCTION
Public health currently faces two epidemics; obesity and type 2 diabetes mellitus
(T2DM). Worldwide obesity has nearly doubled since 1980. Approximately 1.6 billion
adults are overweight with close to 500 million being considered obese (WHO, 2011).
About two-thirds of adults in the United States are considered overweight or obese.
Along with the rise of adult obesity, childhood obesity in the US has tripled over the past
three decades (Flegal et al., 2010; Kalaupahana et al., 2012). According to the World
Health Organization, 382 million people worldwide are afflicted with diabetes and in the
United States 18 million people suffer from this disease (WHO, 2011; CDC, 2009). In
addition, 90% of individuals suffering from type 2 diabetes mellitus are obese or
overweight and are at an increased risk for cardiovascular morbidity and mortality.
Cardiovascular disease is the number 1 cause of death in obese and diabetic individuals
(Ogden, 2009).
Obesity and T2DM are both chronic low-grade systemic inflammatory diseases.
These inflammatory responses are due to changes in adipose tissue depots and immune
cell infiltration that lead to expression of pro-inflammatory cytokines. These proinflammatory cytokines are believed to play a role in inducing insulin resistance, lipid
accumulation in non-adipose sites, and metabolic changes in various organs such as the
liver, skeletal muscle, and the heart (Kalupahana et al., 2012; Kahn et al., 2006). These
pro-inflammatory cytokines are detrimental to the myocardium and can lead to the
development of cardiac dysfunction, fibrosis, cardiomyopathies, and eventually to heart
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failure. However, lifestyle interventions, such as exercise or caloric restriction, may be
able to improve these conditions and induce an anti-inflammatory state. Though there is
limited information on the effect of these two treatments.
In this study, the inflammatory-related changes that occur in the myocardium of
overweight and insulin resistant rats in response to exercise and caloric restriction were
explored. To determine if either intervention attenuated myocardial dysfunction and
inflammatory signaling, an evaluation of activity of a major inflammatory transcription
factor, nuclear factor kappa B (NF-κB) and inflammation-related gene expression in the
heart was completed.

2

CHAPTER 2
LITERATURE REVIEW
2.1 Introduction
This literature review will detail cardiometabolic syndrome and two of the main
factors affecting it: obesity and insulin resistance. Specifically, the role of inflammation
on the myocardium will be highlighted. Nuclear factor kappa B (NF-κB) will be
introduced for its role in inflammation related to cardiometabolic syndrome and lifestyle
interventions of exercise and caloric restriction will be reviewed as methods to improve
inflammatory-related myocardial dysfunction as defined by fibrosis and tissue damage.

2.1.1 Cardiometabolic Syndrome
Cardiometabolic syndrome, commonly referred to as metabolic syndrome or
Syndrome X, is a cluster of multiple cardiovascular, metabolic, pro-thrombotic, and
inflammatory abnormalities, which cause disruptions in energy storage and utilization.
These cardiovascular and metabolic disruptions, individually and together, lead to an
increased risk in the development of cardiovascular disease (CVD) and stroke (Castro et
al., 2003). Cardiometabolic syndrome is becoming a growing concern. Globally, an
estimated 25% of the world population is believed to suffer from cardiometabolic
syndrome. In the United States, this syndrome affects nearly 44% of the elderly
population over the age of 50. Approximately one-third of the US population age 20 and
above already exhibit the criteria for cardiometabolic syndrome (Ford ES, 2005).
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Cardiometabolic syndrome is diagnosed when a patient exhibits three out of five
co-occurring risk factors: 1) abdominal adiposity (obesity), 2) hypertension, 3) insulin
resistance, 4) dyslipidemia, and 5) reduction in high density lipoprotein (HDL) (Hertle et
al., 2014; Kaur, 2014). Individuals suffering from these risk factors, especially
individuals suffering from obesity as well as insulin resistance, are more prone to
manifest other components of the cardiometabolic syndrome such as: an increased
inflammatory state, increased oxidative stress, microalbuminuria, an increased risk of
developing type 2 diabetes mellitus (T2DM) and endothelial dysfunction (Isomaa et al.,
2001).
Aside from physiological risk factors, environmental, personal, and genetic traits
can also contribute to cardiometabolic syndrome. Indeed, sedentary lifestyle, excess
energy intake, genetic susceptibility, and stress play a role in the development of
cardiometabolic syndrome (Cameron et al, 2004). When genetic or environmental
factors, such as physical inactivity, advancing age, and high saturated fat-simple
carbohydrate diet (Western Diet) concomitantly occur alongside obesity, the
cardiometabolic syndrome is exacerbated (Grundy, S 2006). These individuals are three
times more likely to develop coronary heart disease (CHD) and stroke and have two
times the risk of dying from a cardiovascular event (Kaur, 2014). Thus, it is important to
identify individuals at risk and establish early interventions that prevent the development
of CVD, stroke and CHD.
Cardiometabolic syndrome is a progressive disorder that worsens over time
(Grundy, S 2006). The pathogenesis of cardiometabolic syndrome is known to include
two related conditions; insulin resistance and obesity (Grundy et al., 2005). It is well
4

known that insulin resistance and obesity induce dysfunction and physiological damage
to the myocardium and various tissues/organs. The cause of the dysfunction in multiple
tissues and organs may be due to inflammation from excess adipose tissue, endothelial
inflammation, and alterations in the metabolism of these various tissues/organs due to
insulin resistance and adipose tissue (Romacho et al., 2014).
Most studies evaluating the relationship between obesity, insulin resistance and
myocardial dysfunction have used dramatic models of the disease or condition. It is
unknown what changes occur to the myocardium in early stages of obesity (overweight)
or insulin resistance. Understanding the early effects of obesity and insulin resistance on
the heart and the influence of early lifestyle or pharmacological interventions can help
prevent patients from developing T2DM and CVD.

2.1.2 Obesity, Type 2 Diabetes Mellitus and Insulin Resistance
Although there are many factors that influence cardiometabolic syndrome, obesity
and insulin resistance (which progresses to T2DM) are considered the main underlying
causes and greatly influence changes in the heart. Obesity is defined as excess or increase
in adiposity that is detrimental to an individual’s health and resulting in a body mass
index (BMI) ≥ 30 kg/m2 (WHO, 2011). Obesity is a growing epidemic that is afflicting
millions of people in the world and United States. Worldwide obesity has nearly doubled
since 1980. Approximately 1.6 billion adults are overweight with close to 500 million
being considered obese (WHO, 2011). About two-thirds of adults in the United States are
considered overweight or obese. Along with the rise of adult obesity, childhood obesity
in the US has tripled over the past three decades (Flegal et al., 2010; Kalaupahana et al.,
2012), highlighting the need to generate and evaluate effective therapies for the
5

condition. Obesity is considered the 5th leading cause of mortality worldwide (WHO,
2011). In the United States alone, the estimated annual healthcare cost of treating obesity
is approximately $147 billion dollars (CDC, 2011). Obese individuals are at an increased
risk of non-communicable diseases such as various forms of cancer, diabetes, kidney
diseases, and cardiovascular disease (WHO, 2011). Indeed, 70% of all CVD causes are
related to obesity and 112,000 deaths each year are associated to obesity and CVD (NIH,
2013). Therefore, prevention of obesity can help reduce the mortality and morbidity both
of obesity and CVD and reduce the expense associated with treating these diseases.
As with obesity, type 2 diabetes mellitus (T2DM) is another growing epidemic in
the United States and around the world. Type 2 Diabetes Mellitus (referred to previously
as non-insulin dependent diabetes or adult-onset diabetes) is a progressive metabolic
disorder that is characterized by insulin resistance and dysfunction of pancreatic β-cells
(Beck-Nielson et al., 1994). According to the World Health Organization, 382 million
people worldwide are afflicted with diabetes and it is projected to be the 7th leading cause
of death by the year 2030 (WHO, 2013). In the United States, the number of individuals
suffering from diabetes have tripled between 1980 and 2008, increasing from 5.5 million
to 18 million (CDC, 2009; Kalupahana et al., 2012). Cardiovascular disease (CVD) is the
leading cause of death in individuals with type 2 diabetes mellitus (WHO, 2013;
Kalupahana et al., 2012; Kahn et al., 2006).
Both obesity and T2DM are chronic and complex diseases whose causes can also
be attributed to genetic and environmental factors (Wang, Z & Nakayama, T., 2010).
Both diseases are linked to one another as 35% of obese individuals suffer from diabetes
while about 90% of diabetics are overweight or obese. Further, individuals who suffer
6

from T2DM and are obese or overweight are two to four times more likely to exhibit
cardiovascular disease (Kalupahana et al., 2012). Insulin resistance appears to be the
main pathophysiological link between obesity and diabetes.
In the normal insulin response, during a fasting state, the liver produces glucose
via gluconeogenesis and glycogenolysis as a means to maintain normal blood glucose
concentrations. During the consumption of a meal, the intestines become a major site of
glucose utilization, leading to increases in glucose availability to the pancreas. This in
turn causes the pancreas to secrete insulin (Kalupahana et al., 2012). Insulin allows many
tissues and organs in the body to transport and utilize glucose for metabolism. Insulin
helps maintain normoglycemia, especially in liver, cardiac, adipose, and skeletal tissues.
After insulin is secreted, it plays an important role in inhibiting gluconeogenesis and
glucogenolysis from the liver. This mechanism in turn causes the liver to undergo
glycogen synthesis. In skeletal and cardiac tissue, insulin increases glucose uptake and
utilization. In adipose tissue, it inhibits lipolysis and increases the up-regulation of
lipogenesis.
Insulin resistance is defined as an impaired biological response of insulinsensitive tissues in the body to normal circulation of insulin in the blood, leading to
uncontrollable blood sugar levels. When insulin resistance occurs, the normal tissue
response to insulin is blunted (i.e. decreased insulin sensitivity) leading to relative
hyperglycemia and an increase in plasma levels of free fatty acids (Olefsky and Glass,
2010). To compensate for the resulting hyperglycemia, the β-cells of the pancreas secrete
more insulin. The increased secretion of insulin alleviates the relative hyperglycemia
inducing systemic normoglycemia. However, over time, as insulin resistance in tissues
7

progresses, it can lead to pancreatic β-cell dysfunction and failure. With more circulating
insulin, lipogenesis continues, leading to increases in fat tissue. Another consequence of
insulin resistance is propagation to a pro-inflammatory state (Stumvoll et al., 2005). Early
studies found that obesity and the release of cytokines from adipose tissue plays a major
role in the development of insulin resistance, known as obesity-related insulin resistance.

2.1.3 Inflammation, Insulin Resistance and Obesity
Previously thought to be inert and passive depots for lipid storage, an energy-rich
substrate, adipose tissue and adipocytes were discovered to be a major active endocrine
organ responsible for secreting bioactive factors called adipokines (Trayhurn & Wood,
2004). In 1994, Zhang et al., cloned and sequenced the mouse ob gene and human
homologue, leading to the discovery that this gene encoded a 4.5 kilobase (kb) adipose
tissue messenger RNA that would become known as leptin, thereby identifying adipose
tissue as a major endocrine organ. Adipokines are cell signaling proteins released from
adipose tissue, consisting of classical cytokines and chemokines such as tumor necrosis
factor-α (TNF-α) and interleukins (eg., IL-6, IL-1β, etc.), vasoactive and coagulation
factors, and regulators of lipoprotein metabolism, among others (Mohamed-Ali et al.,
1998). It was through this adipokine secretion, that adipocytes and adipose tissue were
discovered to play a central role in a complex and multidirectional network of autocrine,
paracrine, and endocrine crosstalk between organs and tissues such as liver, skeletal
muscle, pancreas, and heart (Romacho et al., 2014). Adipokines can act locally through
autocrine and paracrine signaling within the adipose tissue as a way to regulate local
metabolism. They can also have downstream effects through systemic circulation via
endocrine signaling. Adipokines play a vital role in maintaining insulin sensitivity,
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inflammation, regulation of food intake and body weight, and coagulation or vascular
function (Trayhurn & Wood, 2004; Guzik et al., 2006).
The hypertrophy and hyperplasia of the visceral adipose tissue network due to
insulin resistance and obesity leads to localized inflammatory responses. Inflammation is
defined as a series of cellular and humoral reactions meant to defend the body from
various insults such as infections or tissue damage. The ultimate goal of inflammation is
to restore function and morphological integrity of the affected tissues (Lee & Lee 2014;
Cildir et al., 2013). Inflammation is characterized by increases in local and systemic
cytokine levels along with increased number of infiltrating immune cells. These immune
cells are the first responders in such events. Neutrophils play an important role during
acute phases of inflammation by initiating the immune response, while macrophages take
the stage in more chronic conditions (Lee & Lee, 2014; Mraz & Haluzik, 2014).
Adipose tissue inflammation in obesity has been characterized by macrophage
infiltration, which influences the changes in secretion of pro- and anti-inflammatory
cytokines. Weisburg et al. (2003) used 24 mice with varying degrees of adiposity due to
sex, diet, and obesity-related mutations such as agouti (Ay) and obese (Lepob) to assess
gene expression in perigonadal, perirenal, mesenteric, and subcutaneous adipose tissues
and the potential points of origin. In addition, human abdominal subcutaneous adipose
tissue samples of lean, overweight, and obese subjects were collected. The researchers
used microarrays, PCR, and immunohistochemistry and found over 1,304 transcripts that
were correlated significantly with body mass, an indirect indicator of adiposity. A large
portion of these transcripts encode proteins that are characteristic of macrophages. These
results were further supported by histology data showing macrophage and immune cell
9

infiltration both in mice and human adipose tissues. These data confirmed that
macrophage infiltration correlates with both BMI and adipocyte size and that adipose
tissue macrophages are the primary source of pro-inflammatory adipokines.
Inflamed adipose tissues, especially visceral and subcutaneous, increase their proinflammatory adipokine secretion. These adipokines then leak into the circulation and
potentially alter the microvasculature, various organs, and tissues. Free fatty acids are
released from adipose tissue during this inflammatory response. These free fatty acids
lead to intracellular accumulation of triglycerides, the development of more ectopic fat
(fat that surrounds the organs), and lipid-derived metabolites, exacerbating the
inflammatory response (Unger 2002). This imbalanced adipokine production, especially
the increased secretion of pro-inflammatory adipokines, is observed in metabolic
conditions such as obesity, insulin resistance, and T2DM (Romacho et al., 2014).
Tumor necrosis factor-alpha (TNF-α), an adipokine involved in systemic
inflammation and regulation of immune cells, has been identified as a pro-inflammatory
adipokine important to the development of insulin resistance and obesity. Early research
found that TNF-α was highly expressed in obese and diabetic rodents and that there was a
correlation between the expression of TNF-α and peripheral insulin resistance
(Hotamisligil & Spiegelman, 1993). Translating these findings from rodents to humans, a
follow up study conducted by Hotamisligil et al. (1995), showed that in 19 obese
premenopausal women there was a 2.5 fold increase in TNF-α mRNA expression in
subcutaneous adipose tissue compared to their lean counterparts. They also reported a
positive correlation established between the TNF-α mRNA expression levels in the
adipose tissue and the level of hyperinsulinemia (an indirect measure of insulin
10

resistance). Additionally, obese females were studied before and after a weight loss
intervention targeting a 17% reduction in BMI. These patients exhibited an improvement
in insulin sensitivity and a reduction in TNF-α mRNA expression in adipose tissue. This
study suggests that abnormal cytokine and adipokine production in adipose tissue plays a
role in the pathogenesis of obesity-induced insulin resistance (Hotamisligil et al., 1995)
and that it may be reversible.

2.1.4 Myocardial Fat, Lipotoxicity, and Inflammation in the Heart
Although cardiometabolic syndrome is associated with peripheral fat deposition
and inflammation, it is also associated with adipose accumulation in and around the heart
as epicardial adipose tissue (EAT) and intra-myocardial fat. This fat deposition localized
to the heart likely has a direct effect on cardiac function and may be a major contributing
factor to the high prevalence of heart disease in patients with diabetes and obesity.
In a study by Iacobellis et al. (2003), the researchers were interested in estimating
the volume of epicardial adipose tissue relative to anthropometric, metabolic, and cardiac
parameters of cardiometabolic syndrome using echocardiography. Seventy-two subjects
(36 males and 36 females) were recruited with BMIs ranging from 22 to 42 (median 34).
The subjects were identified as exhibiting cardiometoblic syndrome based on how many
risks factors were present. The researchers found that subjects with predominant visceral
fat accumulation and at least two clinical and metabolic parameters of metabolic
syndrome, showed higher epicardial adipose tissue compared to individuals with
predominant peripheral fat distribution and no clinical parameters. In addition, data
showed that EAT had a strong positive correlation with BMI, waist circumference,
diastolic blood pressure, fasting plasma insulin, LDL cholesterol and plasma adiponectin.
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It was further suggested that individuals exhibiting impaired insulin sensitivity,
independent of BMI, showed the highest epicardial adipose tissue thickness (Iacobellis et
al., 2003). In all, this study positioned cardiac fat as a new cardiovascular risk factor
since it is associated with increased insulin resistance, visceral fat and, in general, with
the metabolic syndrome.
However, the location of cardiac fat may play a pivotal role in its relationship
with obesity, T2DM, cardiometabolic syndrome, and inflammation. EAT comprises
approximately 30% of the intrathoracic fat while the majority is present as extrapericardial fat (PAT); (Sironi et al., 2011). EAT is concentrated in the atrioventricular
and interventricular grooves and along the branches of the coronary artery. EAT is close
to the myocardium and has no real physical barrier to the coronary arteries. PAT is EAT
that is located in these areas along with paracardial fat. Paracardial fat is situated on the
external surface of the parietal pericardium within the mediastinum (Williams, 1995;
Iacobellis et al., 2005; Wheeler et al., 2005; Sironi et al., 2004). This is important since
the amount of fat that can be deposited into the EAT sac is extremely limited, thus, the
majority of fat begins to accumulate in the PAT (Sironi et al., 2012). This has led some
researchers to consider PAT as being more vital in cardiovascular risk management
compared to EAT.
A study conducted by Sironi et al. (2012), using magnetic resonance imaging
(MRI), tested whether EAT or extra-pericardial fat had similar clinical relevance using a
large number of subjects, including patients with T2DM. One hundred thirteen
individuals were recruited (94 men and 19 women) with a mean age of 52 and BMI
ranging from 18 to 40 and 21 had T2DM. The authors looked at all four fat depots:
12

visceral, subcutaneous, epicardial, and extra-pericardial fat. The authors found that all fat
depots increased in proportion to the degree of obesity. EAT and PAT were significantly
correlated with BMI. Visceral fat and PAT were inversely correlated with insulin
sensitivity but not with EAT. In addition, when relating fat depots to CVD risk and
cardiometabolic risk, visceral, PAT, and intrathoracic fat were significantly associated
with three or more cardiometabolic risk factors compared to subcutaneous or EAT.
Further, in a stepwise multiple regression model adjusting for gender and BMI, blood
pressure was only significantly associated with PAT only while insulin resistance and
triglyceride concentrations were best associated both with PAT and visceral fat but not
EAT (Sironi et al., 2012). The authors concluded that visceral fat was the best marker for
altered CVD risk profile while increased PAT was associated with coronary heart disease
risk.
PAT has also been shown to have a high capacity for non-esterified free fatty acid
release and is proposed to be a preferred metabolite source for the myocardium
(Marchington et al., 1989). With the close proximity to the myocardium and the changes,
especially the inflammatory response, that occur with obesity and T2DM, the PAT and
EAT exhibit the same inflammatory changes as observed in visceral adipose tissue.
Indeed, Baker et al. investigated the expression profile of EAT from human EAT of
patients suffering from coronary artery disease. Some of these patients (n=10) exhibited
T2DM but were untreated while also gathering omental, abdominal subcutaneous, thigh
adipose tissues from individuals with no T2DM and CAD. Using PCR and gene
expression assays, Baker et al. (2006) established from their results that EAT exhibits
metabolic risk markers and pro-inflammatory agents, such as TNF-α, IL-6, plasminogen
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activator inhibitor-1 (PAI-1), were similar to omental adipose tissue (visceral) in that of
non-CAD patients. The authors proposed that this pro-inflammatory profile of EAT and
its close proximity to the myocardium may have direct influence on myocardial
metabolism, cardiac dysfunction, lipid accumulation, and macrophage infiltration that
leads to more inflammation (Baker et al., 2006).
The heart is not a major site for lipid storage but fatty acids in the form of
triacylglycerols and phospholipids can be easily stored within the cardiomyocytes. This is
evident in disease states as cardiometabolic syndrome where circulating fatty acids are
high (Gastaldelli et al., 2012). The accumulation of these lipids deposits changes cardiac
metabolism. Normally, the mammalian heart is able to obtain its energy from a balance of
fatty acid and carbohydrate oxidation. Under the conditions of inflammation, lipid
accumulation and insulin resistance, the heart begins to lose the ability to oxidize
carbohydrates and then relies on fatty acids. This in turn causes the heart to rely on βoxidation, then glucose oxidation is downregulated and this leads to the production of
damaging intermediates such as reactive oxygen species (ROS), ceramides, and
diacylglycerols that advance cardiac insulin resistance and promotes lipotoxicity (Kok et
al., 2012; Lewin et al., 2008). Lipotoxicity is defined as the alteration to the intracellular
signaling within metabolic tissues due to lipids and lipid utilization (Wende et al., 2012).
Lipotoxic cardiomyopathy is a disorder of the myocardium induced by the damaging
effects of free fatty acids and inflammation and is characterized by mitochondrial
dysfunction, cardiomyocyte apoptosis, and contractile dysfunction. Further, lipotoxicity
influences sarcoplasmic reticular Ca2+ stores to propagate contractile dysfunction while
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increasing oxygen demand in the heart, exacerbating myocardial damage (Turer et al.,
2012).
This lipotoxic heart has been witnessed in individuals diagnosed with T2DM.
Indeed, an autopsy study conducted by Nakanishi & Kato (2014) investigating fatty
hearts and changes in adipose triglyceride lipase of seventy-three hearts found that
patients with diabetes mellitus were more likely to exhibit fatty hearts. These seventythree hearts were randomly collected and tissues were sectioned from the anteroseptal
area or from a different part of the left ventricle if any tissues scars were present. The
tissue sections were subjected to immunohistochemical staining and tissue lipid content
was extracted. The authors found that seven out of seventy-three hearts were fatty hearts.
These seven hearts were identified as positive for lipid deposition and these individuals
were clinically diagnosed with T2DM. Compared to the non-lipid deposited hearts,
patients with these fatty hearts had significantly higher incidences of myocardial
infarctions and heart failure. In addition, the fatty hearts from the diabetic cases exhibited
significantly elevated triglyceride content in the myocardium compared to non-T2DM
cases. Interestingly, the adipose triglyceride lipases were intact and no changes were
noted in all cases. It can be postulated that these changes in the myocardium were not due
to over-activation or changes to adipose triglyceride lipases, thus, it is possible that
diabetes is associated with myocardial lipid accumulation and inflammation may play a
role in this accumulation process.
The authors of this study found the hearts of patients from the diabetes cases
experienced more severe histological damage than non-diabetes mellitus cases. Due to
this higher incident, it appears that individuals with T2DM are more susceptible to
15

cardiomyopathies. Further, the authors believe that this histological damage may not be
due to lipid deposition alone, but may be correlated more with the factors secreted from
epicardial adipose tissue. Indeed, individuals with T2DM have increased EAT depots and
the factors released from the EAT are associated with the development of cardiomyocytes
dysfunction. EAT is known to be metabolically active and produces adipokines such as
TNF-α, IL-1, adiponectin, IL-6, and free fatty acids (Mazurek et al., 2003). Thus, an
interaction between lipid accumulation, epicardial adipose tissue, and secreted factors
likely plays a role in the development of cardiomyopathies and cardiac dysfunction in
diabetic cases, though the role of inflammation in early stages of the disease progression
needs further investigation.

2.1.5 Role of NF-κB
Inflammation is defined as a series of cellular and humoral reactions meant to
defend the body from various insults such as infections or tissue damage. The ultimate
goal of inflammation is to restore the function and morphological integrity of the affected
tissues (Lee & Lee 2014; Cildir et al., 2013). Nuclear factor kappa B (NF-κB) represents
one of the many key systems that mediate both neurohormonal and pro-inflammatory
signals, especially in hypertrophy and fibrosis of the heart (Pechanova & Simko, 2010).
NF-κB initiates the coordinated expression of inflammatory responses in the
myocardium, which includes the increased expression of pro-inflammatory cytokines,
chemokines, and cell adhesion molecules (Hernadez-Presa et al., 1997; Luft, 2001;
Sekiguchi et al., 2004). This pathway is not only responsible for inducing a proinflammatory response but it also can exhibit protective responses.
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In mammals, the NF-κB super family of transcriptional factors consist of at least
five genes that encode the members RelA (p65), RelB, c-Rel, p50, and p52 (Hayden &
Ghosh, 2008). All of these members are conserved throughout evolution and share a Rel
homology domain (RHD), allowing DNA binding and dimerization between members.
Transcription by NF-κB only works when two members form a heterodimer. In the heart
the most predominant heterodimer is p50/p65 complex. With all transcription factors,
nuclear localization is necessary for down-stream gene transcription. Indeed, if no signals
are active, NF-κB exists as an inactive dimer in the cytoplasm of cells bound to its
inhibitor (IκB) proteins (IκBα,-β,-ε) (Gordon et al., 2011).
To induce activation of NF-κB, phosphorylation-dependent degradation of IκB
proteins via a proteasomal regulated pathway must occur. This phosphorylation is a key
step in NF-κB activation and is mediated by IκB-kinase (IKK). Liberating NF-κB from
its inhibitory complex causes NF-κB to become active and translocate to the nucleus,
where it begins to bind to the promoters or enhancer regions of target genes containing a
consensus motif 5’-GGGRNWYYCC-3’ (R=any purine, N=any nucleotide, W=adenine
or thymidine, Y=any pyrimidine) and commencing transcription (Gordon et al., 2011;
Pechanova & Smiko, 2010). Indeed, NF-κB transcription and activation has been found
in various models of cardiac hypertrophy, hypertension, myocardial ischemia, and
cardiac remodeling (Pechanova & Smiko, 2010; Kupatt et al., 1999).
Li et al. (2004) was one of the first groups to show that NF-κB activation is
required for the development of pathological cardiac hypertrophy in vivo. The researchers
used male Sprague-Dawley rats and separated them into two groups: an aortic band group
to elicit hypertrophy and a sham operated group (n=8 -10 in each group). The aortic band
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group had binding of the ascending aorta with silk sutures while the sham group had
small incisions made to mimic the surgery but no actual banding occurred. In a similar
group, the researchers used transfection of an IκBα dominant negative mutant super
repressor of NF-κB activation and PDTC, an antioxidant that has been shown to inhibit
NF-κB activation, to determine if these interventions can attenuate hypertrophy in these
animals. First, aortic binding lead to hypertrophy in the hearts of the aortic band group
compared to the age-related sham group. To verify, real time PCR was used to examine
gene expression of two genes related to cardiac hypertrophy, ANP (atrial natriuretic
peptide) and BNP (brain natriuretic peptide). ANP and BNP mRNA gene expression
levels were increased in the aortic band group compared to the sham, showing that
cardiac hypertrophy did occur. Using electrophoretic mobility shift assays (EMSA), they
found increased NF-κB binding activity in hypertrophied hearts. Along with the increase
in NF-κB binding activity, IKKβ activity was also increased. In addition, using their
transfection of IκBα and PDTC, they found that they could attenuate the development of
cardiac hypertrophy in vivo. This study demonstrated that NF-κB activation is required
for the development of cardiac hypertrophy and that inhibiting NF-κB attenuates this
detrimental hypertrophy. Interestingly, the researchers stated that ANP & BNP gene
expression requires NF-κB activation and that the increased expression was
representative of cardiac hypertrophy (Li et al., 2004; Liang & Gardner, 2001; Purcell et
al., 2001). However, in conditions such as obesity and diabetes, inflammation may play a
role in the activation of NF-κB in the heart.
Inflammation and microbial products can also activate NF-κB. Pro-inflammatory
markers such as TNF-α or IL-1β can activate NF-κB through what is considered to be the
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“canonical pathway”. In this pathway, the IKK dimer that consists of IKKα and IKKβ
are activated by TNFR (TNF-α) receptor 1, interleukin-1 receptors (IL-1R) and other proinflammatory cytokine receptors. The binding at these locations causes the recruitment of
signal adaptors like myeloid differentiation primary response gene 88 (MyD88) that
result in the activation of tumor necrosis factor receptor-associated factor (TRAF6).
TRAF6 allows for auto-ubiquitination to occur which, in turn, allows for the recruitment
of other intermediates that phosphorylate IKK. Indeed, TRAF6 along with receptor
interacting protein (RIP) help create a scaffold for binding of pro-inflammatory kinases
TAK1 that phosphorylate IKK (Van der Heiden et al., 2010). Majority of the literature
that focuses on the non-canonical pathway has been on lymphocytes and information on
other cell types is limited. Thus we will mainly focus on the canonical pathway.
In a recent study by Thomas et al. (2014), the 3M mouse was used to study the
protective effects that NF-κB suppression would have in diabetes-induced cardiac
dysfunction. The 3M animal model is a cardiac-specific transgenic mouse model that
overexpresses IκBα with a triple mutation that prevents its phosphorylation, thus
suppressing the canonical NF-κB pathway. The authors used C57B1/6J wild type mice as
a control group and another group of these same mice as diabetic models. 3M mice and
some of the wild-type C57B1/6J mice were given streptozotocin (STZ) to induce diabetes
while animals in the control groups were given a placebo vehicle. Animals underwent
echocardiography to determine cardiac function and after 24 weeks were sacrificed and
heart tissues extracted. Western blots and real-time PCR were conducted using RNA
extracted from heart tissues. The researchers found that in the hearts of the diabetic wildtype mice, through DHE staining, an increase in oxidative stress compared to the 3M
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diabetic and control group was witnessed. The 3M control mice initially exhibited
oxidative stress but greater levels were observed in the wild-type diabetic mice after 24
weeks. Molecular markers such as β-myosin heavy chain (β-MHC), ANP, and BNP were
increased in wild-type diabetic mice and not in the 3M diabetic mice. As stated
previously, ANP and BNP need NF-κB activation to increase their expression. Lastly,
compared to wild-type diabetic mice, the 3M diabetic mice lacked an increase in the p65
subunit of NF-κB in the nuclei, which correlated with decreased NF-κB activity in these
mice.
The 3M mouse mutation is cardiac-specific. Thomas et al. (2014) observed that
lack of NF-κB activation protects animals from developing diabetic cardiomyopathy.
Canonical NF-κB activation in the diabetic myocardium is required for cardiac
remodeling. As evidenced by their results, genetic silencing of NF-κB, specifically in the
heart, helps prevent diabetic cardiomyopathies. In addition, the levels in plasma and
expression in tissues of pro-inflammatory cytokines have been shown to change with
time in T1DM and T2DM but the authors observed no increase in expression of
inflammatory cytokines such as IL-1β, IL-6, or TNF-α. This is supported by studies in
streptozotocin treated rats.
Other stimuli can affect the canonical NF-κB pathway. Hypoxia, ROS, and
mechanical stretch are known to be effective activators of the canonical pathway. Indeed,
in conditions like diabetes and obesity, where states of inflammation are chronic, NF-κB
may be overly stimulated (Arkan et al., 2005; Bierhaus et al., 2001). This overt
stimulation promotes more NF-κB transcription of inflammatory markers. Some of these
pro-inflammatory markers such as matrix metalloproteinases, TNF-α, IL-1β, and MCP-1
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that are active during cardiomyopathy are regulated by NF-κB (Van der Heiden et al.,
2010).
In conclusion, the NF-κB family controls multiple processes, including immunity,
inflammation, cell survival, differentiation, and proliferation. Pro-inflammatory
cytokines, reactive oxygen species, and microbial products can induce NF-κB signaling,
resulting in transcriptional regulation of pro-inflammatory genes such as TNF-α, IL-8,
IL-1β, MCP-1, and many more, which promote the inflammatory process. Indeed,
diabetes and obesity are both conditions with chronic subclinical inflammation that
affects NF-κB. Individuals suffering from diabetes and obesity are more likely to exhibit
over-activation of NF-κB. NF-κB has been shown to play a role in the development of
cardiac hypertrophy and cardiac dysfunction in these individuals. However, there
currently exists little data on the effects of NF-κB in the earlier stages of disease
(overweight and insulin resistance) in the heart and whether interventions such as
exercise or caloric restriction can alter or prevent pathology.

2.1.6 Detection of Molecular Pathology in the Heart
When pathophysiological stresses are introduced in the heart, certain genes are
activated as a way to compensate and remodeling of the heart occurs. A wellcharacterized adaptation of the heart to stress is the fetal gene program or the activation
of genes that are expressed during early fetal circulation but become silent as the
mammalian heart ages. The expression of genes in this group play an important role in
cardiovascular diseases such as cardiac hypertrophy (Kuwahara et al., 2012; Bernado et
al., 2010) and may be useful in characterizing cardiac dysfunction due to obesity and
diabetes or insulin resistance. The genes involved in this program are: atrial and brain
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natriuretic peptide (ANP and BNP, respectively), fetal isoforms of contractile proteins
(skeletal α-actin and α-, β-myosin heavy chain), fetal-type cardiac ion channels
(SERCA2a), and smooth muscle genes (smooth muscle α-actin); (Kuwahara et al., 2012;
Bernado et al., 2010).
ANP & BNP are peptide hormones that are encoded by the Nppa and Nppb genes,
respectively. These hormones are secreted in the adult heart in response to cardiac wall
stretch and strain (Dietz, 2005). ANP is released by atrial cardiomyocytes while BNP is
released from ventricular cardiomyocytes. Both hormones respond to high blood pressure
(cardiac wall stretch and strain) and act to reduce water, sodium, and adipose loads to
induce a decrease in blood pressure. However, both ANP and BNP have been discovered
to antagonize cardiac hypertrophy, fibrosis, and to stimulate lipolysis (breakdown of
lipids into fatty acids/triglycerides); (Cox et al., 2014; Rosenkranz et al., 2003; Franco et
al., 2004; Wang et al., 2003).
The sarcoplasmic reticulum Ca2+ ATPase 2 (Serca2a) is another important
member for the fetal gene program. Serca2a is responsible for the re-uptake of calcium
into the sarcoplasmic reticulum following the contraction of the sarcomere, allowing
muscular relaxation. Serca2a expression levels are maintained through adulthood but a
decrease is observed in the diabetic heart and may play a role in the diastolic dysfunction
that leads to diabetic cardiomyopathy (Cox et al., 2014).
The myofilament proteins α-myosin heavy chain (α-MHC) and β-myosin heavy
chain (β-MHC) exhibit different properties and their ratio is changed during cardiac
hypertrophy. α-MHC, which has the highest ATPase activity and contractile velocity, is
highly-expressed during adulthood while β-MHC, which has the lowest ATPase activity
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and lowest contractile velocity, is highly-expressed during fetal development. A ratio
between α-MHC and β-MHC exists which is maintained in adulthood. However, during
cardiac hypertrophy, the ratio decreases. It is important to note that humans exhibit more
β-MHC than α-MHC. Rodents exhibit the α-MHC/β-MHC ratio as described previously
(Gustafon et al., 1987; Lyons et al., 1990; Reiser et al., 2001; Miyata et al., 2000). In
addition to the myosin cytoskeletal proteins, skeletal α-actin changes in the hypertrophied
heart. Skeletal α-actin is highly-expressed in the fetal heart and is replaced by cardiac αactin in adulthood. During cardiac hypertrophy and cardiac dysfunction, there is a reexpression of and conversion to skeletal α-actin (Driesen et al., 2009; Ren et al., 2012).
Some evidence suggests that the fetal gene program is activated in diabetes. In a
study conducted by Depre et al. (2000), Wistar rats were injected with β-cell toxin
streptozotocin (STZ) to induce T2DM while another group of Wistar rats was injected
with vehicle only to serve as a control group. The animals were then sacrificed and RNA
was extracted from the animals’ heart tissue. The authors used polymerase chain reaction
(PCR), to assess the gene expression of a myriad of contractile proteins and ion pumps.
The researchers found that the gene expression of many of the contractile proteins and
ion pumps (e.g. SERCA2a, β-/-α MHC) were decreased in the diabetic hearts and
exhibited the same gene expression as what is observed in the hypertrophied heart.
In addition to the fetal gene program, cardiac pathology related to diabetes and
obesity may be evident as fibrosis. Yagi et al. (1997), characterized the changes in the
myocardium of the Otsuka Long-Evans Tokushima Fatty rat (OLETF), a genetic animal
model of mild obesity and non-insulin dependent T2DM, evaluating fetal gene expression
and genes involved in cardiac fibrosis as markers for changes in cardiac performance. In
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this study, the Long-Evans Tokushima-Otsuka (LETO) rats were used as a genetic
control for the OLETF rats. LETO rats are lean rats and are from the same colony that the
OLETF come from, thus having the same genetic background. The hearts of animals
were characterized at week 14 (a pre-diabetic state), week 30 (non-insulin dependent
diabetes mellitus phase), and week 54 (insulin dependent diabetes mellitus phase) by left
ventricle mRNA expression. The researchers found that although there were no
differences between fetal gene expression program markers at 14 weeks, at 30 weeks,
OLETF left ventricle expression of β-MHC was greater than LETO. mRNA levels for
contractile proteins α-/β-MHC and ANP, and were significantly different between groups
at 54 weeks. Specifically, α-MHC mRNA levels were lower and ANP mRNA levels
were 1.3-fold higher in the OLETF rat compared to the LETO at 54 weeks. This data
indicates that β-MHC expression differences appear early in the progression of the
OLETF disease phenotype whereas other fetal gene program indicators of dysfunction do
not appear until later in this model.
There is evidence that cardiac fibrosis occurs at early time points in the OLETF
model and that it may be related to inflammation. Yagi et al. (1997), reported that at 14
weeks of age, the left ventricular gene expression of collagen types I, III and IV, along
with laminin, were significantly enhanced in OLETF compared with LETO rats of the
same age. Collagen types III and IV and laminin mRNA levels remained elevated in
OLETF rats at week 30 compared to LETO. Transforming Growth Factor-β (TGF-β) is a
pleiotropic cytokine that can regulate fibrogenesis and is released from pro-inflammatory
cells (e.g. macrophages). The authors showed that mRNA levels of 14-, 30-, and 54week-old OLETF rats were 1.5-, 1.6-, and 1.3-fold greater, respectively, than in the
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LETO rats examined at those same time points. Thus, markers of fibrosis are evident at
early stages in the OLETF model when animals are overweight and insulin resistant.
Importantly, although OLETF rats develop hypertension, authors reported no
alterations in cardiac TGF-β or β-MHC in genetically hypertensive rats (SHR) suggesting
different regulation of cardiac pathology between hypertension and diabetes/obesity
(Yagi et al., 1997). The involvement of TGF-β in cardiac fibrosis in this pre-diabetic
stage is still unclear. Inflammation may play a role in linking TGF-β and cardiac fibrosis
in the OLETF rat. Exploring cardiac fibrosis gene expression in young OLETF rats and
its interaction with inflammation may provide further insight into the genetic and
molecular pathways that may exacerbate the risk of CVD in obese and diabetic
individuals.

2.2 Role of Exercise and Caloric Restriction
2.2.1 Exercise
Exercise is well-known to be a powerful treatment for obesity-related metabolic
complications, including insulin resistance, hypertension, impaired glucose tolerance or
diabetes, hyperinsulinemia, and dyslipidemia that are characterized by elevated adipose
accumulation (Kim et al., 2008; Hu et al., 2001; Tuomilehto et al., 2001). A study by Hu
et al. (2001), that followed approximately 85,000 female nurses for 16 years, found that
adopting a healthy diet and physical activity reduced obesity, risks for cardiovascular
disease, and chances of developing cancer and other chronic diseases. In addition,
physical activity improves glucose homeostasis and insulin sensitivity, coronary blood
flow and cardiac function, enhances endothelial function, and reduces blood pressure
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(Murphy et al., 2009). These improvements in cardiac function may be related to a
reduction in overall fat mass and pro-inflammatory state, systemically and at the level of
the myocardium. However, understanding the independent effect of exercise from
weight or fat loss is difficult given that many studies do not control fat loss.
Trachta et al. (2014) investigated the effects of regular physical activity on
improving systemic sub-clinical inflammation and other obesity-related pathologies
through the modulation of inflammatory profile of adipose tissue. Fifteen non-diabetic
obese females with arterial hypertension were recruited for the study and were placed in a
three-month aerobic exercise program consisting of 30 minutes of aerobic exercise for
three times a week. Fifteen healthy lean women that were free of any cardiovascular and
metabolic parameters were selected to serve as a control group. Subcutaneous adipose
tissue samples were collected from the abdominal region and RNA was extracted and
used in PCR to examine pro-inflammatory gene expression. After their intervention,
Trachta et al. (2014) found that regular aerobic exercise significantly decreased body
weight and body fat, systemic sub-clinical inflammation, and insulin resistance. Though
the exercise intervention did not have much effect on the endocrine function, there was
an improvement in the pro-inflammatory gene expression such as chemokine C-C motifs
2, 3, 4, IL-1β, IL-6, for example, in subcutaneous adipose tissue. The obese non-diabetic
women exhibited a decrease in a myriad of pro-inflammatory cytokines though not
statistically significant. In addition, the authors noted that though the subcutaneous
adipose tissue is the largest of the fat depots, it is not a major player in systemic
inflammation compared to visceral adipose tissue. Since the non-diabetic obese
participants had a reduction in waist circumference, it can be postulated that the reduction
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in visceral adipose tissue due to aerobic exercise lead to improvements in systemic
inflammation.
Longitudinal studies have shown that daily physical activity helps combat
inflammation by reducing adiposity and thus diminishing the macrophage infiltration. In
studies that looked at 12-week interventions of sedentary males with metabolic
syndrome, they found that moderate-intensity exercise reduced inflammatory markers
such as MCP-1 and IL-8. Similar results in other studies investigating individuals with
heart failure found a reduction in pro-inflammatory markers and an increase in antiinflammatory proteins (Goldhammer et al., 2005). Markers such as IL-1, MCP-1, and Creactive protein (CRP), which is released from the liver, were all significantly reduced
compared to levels in individuals who did not exercise. Importantly, these benefits were
evident even in the absence of significant weight loss (Goldhammer et al., 2005). In
addition, exercise is able to attenuate insulin resistance and improve insulin sensitivity in
many different tissues, including the heart. Thus, exercise can be an effective treatment
for obesity and T2DM, especially if they both exist concomitantly (Dalzill et al., 2014).
Kim et al. (2008) conducted a study to determine whether three-months of aerobic
exercise training without caloric restriction (by having the participants maintain a food
log and normal eating habits) produced changes in EAT and its relation to abdominal
visceral adipose tissue changes. Twenty-four obese middle age Japanese males were
recruited. The participants were supervised by an exercise physiologist for compliance
and aerobic exercise intensity was based on the individual’s maximal heart rate attained
from an initial aerobic fitness test. The researchers found that EAT thickness (measured
by echocardiography) was reduced in obese men after a three month aerobic exercise
27

intervention, compared to pre-intervention. Interestingly, the percent change in EAT was
twice as high compared to changes in waist, BMI, and visceral adipose tissue. In addition,
the reduction in EAT was accompanied by a reduction in the visceral adipose tissues.
Some participants in this study exhibited the cardiometabolic syndrome according to the
Japan Society for the Study of Obesity criteria and exhibited improvement in insulin
sensitivity and fat reduction both in visceral and epicardial adipose tissue. This study was
the first study to show that exercise has a potent effect in reducing EAT thickness and
improving biological markers associated with obesity and cardiometabolic syndrome.
Kim et al. (2008) published one of the first studies investigating the effects of
exercise on the heart, especially on EAT, and it did not include caloric restriction as part
of their intervention. Many studies use a combination of exercise and calorie restriction in
their interventions and the outcomes that are presented cannot be attributed either to
exercise or caloric restriction alone. Many agree that weight loss improves many of the
outcomes in obesity and diabetes. The mechanisms behind the direct effects of exercise
on the heart and other tissues are still heavily investigated areas. In all, exercise may
prove to be an effective intervention for improving inflammation and cardiac dysfunction
in individuals with cardiometabolic syndrome.

2.2.2 Caloric Restriction
Caloric restriction (CR) is classified as a state in which the energy intake of an
individual or animal is minimized to low-normal levels while maintaining a balance of
macronutrients like protein and carbohydrates. CR usually consists of about 30-50%
reduction in energy intake that is required to maintain normal body weight and adiposity,
leading to a leaner phenotype. In animal studies, it is usually administered early in the
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animal’s life so that there is no weight loss and the changes are attributed to the condition
of CR and not weight loss. In humans, it is administered in adulthood, where the results
can be contributed to weight loss or the caloric restriction itself. Therefore, in humans,
determination of the independent effects of CR versus weight loss is difficult (Weiss &
Fontana, 2011).
With respect to the heart, CR may prove to be an effective intervention for
individuals who are obese and/or diabetic. Hammer et al. (2008) studied the effects of
prolonged caloric restriction in 12 obese patients with T2DM on myocardial triglyceride
content and cardiac function. The intervention lasted for 16 weeks and the participants
had their myocardial triglyceride content and left ventricle function measured through
photon magnetic resonance spectroscopy. The authors found that the caloric restriction
had reduced the BMI of the patients and improved many of their metabolic parameters.
Indeed, the participants had improved glycemic control (decreases in fasting plasma
glucose levels), and hemoglobin A1c levels, plasma non-esterified fatty acids, and liver
enzymes such as CRP (inflammatory biomarker), were all reduced after prolonged caloric
restriction. In addition, myocardial triglyceride content and left ventricular mass
decreased while improving cardiac output and both systolic and diastolic blood pressure.
The effects of caloric restriction on EAT were further supported by the work of
Iacobellis et al. (2008). In this study, 20 severely obese subjects (BMI≥40 kg/m2)
underwent a very low calorie (900 calories) diet weight loss program for 12 weeks.
Anthropometric measures were taken and epicardial adipose tissue was measured using
echocardiograms. Iacobellis et al. found that severely obese subjects had significantly
higher epicardial fat thickness compared to lean subjects. After the intervention, the
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subjects decreased their body weight and BMI by approximately 20%, had a 23%
reduction in their waist, and a 32% reduction in epicardial fat thickness. In addition, left
ventricular mass (LVM) was significantly reduced and improvements in diastolic
function were witnessed. These changes all correlated strongly with the decrease in
epicardial fat thickness. Thus caloric restriction, even for a short period, can elicit
powerful changes and improvements in the myocardium, especially in severely obese
individuals.
Though there may be some differences in administration of CR, evidence shows
that in animals and humans, CR is able to increase longevity and reduce death due to
chronic diseases such as cancer, T2DM, obesity, and cardiovascular disease. Indeed,
research has shown that CR is able to attenuate the production of ROS and oxidative
damage by activation of SIRT1 and transcription factor NF-E2-related factor (Nrf2). In
addition, CR is able to attenuate age-related vascular inflammation by improving the NFκB inhibition of pro-inflammatory gene transcription, thereby causing NF-κB to become
active in anti-inflammatory gene transcription and reducing a pro-inflammatory state.
Lastly, like exercise, CR is able to reduce adiposity and inflammatory markers, especially
in the cardiovascular system, leading to healthy cardiovascular function and can even
decrease the adverse effects of cardiomyopathy (Weiss & Fontana, 2011; Kemi et al.,
2000).

2.2.3 Comparative Effectiveness of Exercise and Caloric Restriction
Comparative effectiveness studies are novel ways to inform health-care decisions
by providing evidence of the effectiveness, benefits, and/or detriments of different
treatment options. Few studies have looked at comparative effectiveness of exercise or
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caloric restriction on pathologies of the heart, especially in early overweight and insulin
resistance. Both exercise and caloric restriction are beneficial for improving
cardiovascular health in individuals who suffer from cardiometabolic syndrome,
however, no studies have been conducted to determine which is more beneficial.
A report by Crissey et al. (2014) is one of the few that has compared exercise to
caloric restriction for changes related to cardiometabolic syndrome. The researchers used
OLETF rats to study the changes in the various adipose tissue depots either through
exercise or caloric restriction in relation to vascular insulin resistance and inflammation.
The study was conducted using 30 male OLETF rats that were purchased and randomized
into 3 groups: sedentary (SED), caloric restriction (CR), and exercise (wheel running;
WR). The animals in the caloric restriction were fed 70% ad libitum, exhibiting a modest
30% caloric reduction. The OLETF rats were placed in each intervention for 8 weeks and
then sacrificed at 20 weeks, at which time the animals present with an early insulin
resistant and overweight phenotype. Perivascular adipose tissue from the thoracic aorta,
retroperitoneal white adipose tissue, inguinal subcutaneous adipose tissue and brown
interscapular adipose tissue were excised from the animals. A portion of the perivascular
adipose tissue was used for in vitro assessment of cytokine secretion. RNA was extracted
from the various adipose tissues and aortic samples. Real-Time PCR was used to
determine gene expression.
The researchers found that the exercise (wheel running; WR) and caloric
restriction (CR) groups had improved body composition, exhibiting lower body fat
percentages and less visceral adipose tissue mass compared to the sedentary group. Both
exercise and caloric restriction groups had improved fasting total cholesterol, LDL
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cholesterol, leptin, glucose, non-esterified fatty acids (NEFA), and triglycerides (Table
4). In addition, the exercise group exhibited improvements in HOMA-IR, lower plasma
insulin, and lower circulating MCP-1. In the retroperitoneal adipose tissue, both WR and
CR groups had lower expression of leptin, MCP-1, TNF-α, IL-6, PAI-1, and intercellular
adhesion molecule-1 (ICAM-1) compared to SED. Expression of these inflammatory
markers were higher in brown adipose tissue, in the WR group only. In the periaortic
adipose tissue, both CR and WR exhibited lower expression of leptin, MCP-1, TNF-α,
with the WR group exhibiting a lower PAI-1 expression compared with the SED group.
In the CR group, the periaortic fat exhibited lower IL-6, E-selectin, and ICAM
expression. Subcutaneous adipose tissue had lower leptin and MCP-1 expression. Insulinstimulated aortic relaxation was significantly greater in WR rats relative to SED and CR
rats (Crissey et al., 2014).
In addition, Crissey at al. (2014) investigated gene expression indicative of
immune cell infiltration into peripheral adipose tissue depots, periaortic adipose, and
aorta to determine if WR or CR was able to attenuate their expression. Markers for
immune cell infiltration, such as cluster of differentiation 4 (CD4), cluster of
differentiation 8 (CD8), and EGF-like module containing mucin-like hormone receptorlike 1 (F4/80), revealed that WR and CR reduced expression of these three markers in the
aorta and retroperitoneal adipose tissue compared with the SED group. Interestingly, WR
and CR both reduced leptin, IL-6 and MCP-1 secretion from periaortic adipose tissue
indicating that immune cells and cytokine release from adipose may contribute to tissue
inflammation in OLETF rats. CD4 and CD8 are markers commonly expressed in
macrophages, monocytes, and T-cells while F4/80 is another macrophage glycoprotein
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receptor that is expressed in high levels in various macrophages and more importantly
can be expressed in macrophages of connective tissue such as the heart (Heidt et al.,
2014; Weisberg et al., 2003). EX and CR were able to attenuate their expression in
adipose tissue and may be able to induce similar changes in the immune cell infiltration
within myocardial tissue.
Overall, these results show the improvements on adipose tissue and inflammation
that can occur either with exercise or caloric restriction. Both can reduce the
inflammatory markers that are detrimental in obesity and insulin resistance that lead to
cardiovascular morbidity and mortality, especially since adipose tissue inflammation
plays a pivotal role in all of these conditions. Indeed, the changes in the periaortic
adipose tissue has huge implications for cardiovascular and myocardium health due to its
close proximity. In addition, the researchers’ data on the effects of exercise and not
caloric restriction on insulin-stimulated vasodilation of the aorta shows that exercise is
able to induce insulin-sensitizing effects on vascular tissue while caloric restriction may
not.
Exercise and caloric restriction both exhibit cardiovascular benefits and decrease
the risks associated with CVD, inflammation, and other chronic conditions. However, it
is unknown which intervention can improve cardiac dysfunction and inflammation
associated with the cardiometabolic syndrome. Investigating the comparative
effectiveness of each of these interventions can elucidate more effective interventions
during early pathology or provide new knowledge on the role of exercise or caloric
restriction in heart health. Our study is novel as there are no studies to date that have

33

compared the effectiveness of each of these two interventions in an early overweight and
insulin-resistant animal model, relative to changes in the myocardium.

2.2.4 Specific Aims and Hypotheses
Cardiometabolic syndrome is becoming a worldwide epidemic, affecting about
25% of the world population. Two of the underlying causes of cardiometabolic syndrome
are obesity and insulin resistance. Cardiometabolic disease, along with obesity and
insulin resistance, increases an individual’s risk of developing cardiovascular disease and
dying from a cardiovascular event. Preventive care and lifestyle modifications such as
diet and exercise are known to alleviate the rate of insulin resistance and obesity, thus
diminishing the number of individuals suffering from cardiometabolic syndrome. Many
of the adverse effects of cardiometabolic syndrome in the heart are due to the chronic
inflammatory state of the disease. There exists a gap in the literature as to whether there
are alterations to the myocardium in early stages of cardiometabolic syndrome and
whether lifestyle interventions, in the form of exercise or caloric restriction,
delay/prevent the development of cardiometabolic syndrome and CVD.
AIM 1: To determine the effect of exercise and caloric restriction to change markers of
cardiac dysfunction in a model of overweight and insulin resistance.
Methods: OLETF rats will be separated into three groups (SED, EX, & CR). After 20
weeks in each condition, heart tissue will be isolated and RNA will be extracted.
Expression of genes related to the fetal gene program (i.e. α-MHC, β-MHC) and fibrosis
(i.e. TGFβ1, Col-1, and COL-3) will be examined in each group.
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Hypothesis 1: Animals in the CR and EX group will exhibit lower expression of cardiac
dysfunction genes compared with the SED group signifying CR and EX as effective
countermeasures for pathological alterations in the heart in young OLETF rats.
AIM 2: To determine the effect of exercise and caloric restriction to alter NF-κβ activity
in the heart in an early model of overweight and insulin resistance.
Methods: Nuclear and cytosolic fractions of OLETF heart tissue will be separated. An
NF-κB DNA-binding activity assay will be used to determine NF-κB activation in SED,
CR and EX groups.
Hypothesis 2: Sedentary animals will exhibit a greater activation of NF-κB in the heart
compared to the CR and EX groups.
AIM 3: To determine the effect of exercise and caloric restriction on gene expression of
inflammatory markers related to NF-κβ activity and monocyte/macrophage infiltration in
the heart in an animal model of early insulin resistance and obesity.
Methods: Using RNA extracted in Aim 1, Polymerase Chain Reactions (PCR) will be
conducted using primers for inflammatory genes such as TNF-α, IL-1β, MCP-1, in
addition to monocyte and macrophage makers such as CD4, CD68, and F4/80, and
determine their relative gene expression in the three conditions.
Hypothesis 3: Exercise and Caloric restriction should exhibit lower expression of
inflammatory genes that are related to NF-κβ signaling and immune cell infiltration
compared with the sedentary group.
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CHAPTER 3
METHODS
3.1 OLETF Animal Model and Characteristics
Otsuka Long-Evans Tokushima Fatty (OLETF) rats are spontaneous diabetic rats
exhibiting polyuria (excessive urine production), polydipsia (excessive thirst), and mild
obesity. This strain of rats was first discovered in 1984 from an outbred colony of LongEvans rats that was purchased from Charles River, Canada in 1982. The Tokushima
Research Institute (Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan) has maintained
this particular diabetic strain of Long-Evans rat through selective breeding and named it
Otsuka Long-Evans Tokushima Fatty rats. Long-Evans Tokushima Rats (LETO) are the
lean, non-diabetic counterparts to the OLEFT rats obtained through different original
mating. However, both rats come from the same strain of Long-Evans rats. The LETO rat
is commonly used as a genetic control group to the OLETF (Kawano et al., 1994;
ChengD & Wang, M-W., 2005).
Otsuka Long-Evans Tokushima Fatty (OLETF) rats exhibit the following
characteristics: 1) late onset hyperglycemia after 18 weeks of age, 2) chronic course of
the disease, 3) mild obesity, 4) clinical onset of diabetes that is exhibited mostly in males,
5) changes to pancreas and kidneys. Beginning at 5 weeks, the OLETF rat begins to
rapidly gain weight, compared to their LETO counterparts. OLETF rats begin showing
high blood glucose concentrations at 18 weeks and impaired glucose intolerance starting
at 24 weeks of age. Plasma triglycerides concentrations start increasing at 8 weeks of age
but cholesterol concentrations slightly increase after 40 weeks. Along with these
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changes, OLETF rats exhibit increased blood pressure at 18 weeks of age compared to
LETO rats (Panchal et al., 2011).
The clinical and pathological features of the OLETF rat closely resembles those
exhibited in humans with Type 2 Diabetes Mellitus (ChengD & Wang, M-W., 2005). For
our study, the OLETF rats were maintained until 20 weeks of age. At this time, the
OLETF rat exhibits an overweight phenotype and early insulin resistance thus
representing a pre-diabetic state. Since the animal model exhibits the clinical and chronic
pathology of type 2 diabetes with mild obesity, this early time point is crucial in
determining if there are early changes in the heart. Other animal models exhibit severe
obesity with diabetes that may not be representative of what is exhibited in humans who
may just be mildly obese and with insulin resistance.

3.1.2 Animal Set Up
All animal protocols were approved by the University of Missouri Institutional
Animal Care and Use committee. For this experiment, male Otsuka Long-Evans
Tokushima Fatty Rats (OLETF) were used and obtained at four weeks of age (Japan SLC
Inc. 3371-8, Kotoh-Cho, Hamamatsu, Shizuoka, Japan) and were individually caged and
maintained in temperature controlled (21°C) with light cycles from 6:00 to 18:00 hour
and dark cycles from 18:00 to 6:00 hour. At 12 weeks, the rats were randomized into
three groups: (I) sedentary (SED; n=10), (II) voluntary wheel running (WR; n=10) and
(III) sedentary + diet restriction (DR, fed 70% of ad libitum-feed SED animals; n=10).
Animals in the wheel running (WR) group were housed with running wheels connected
to Sigma Sport BC 800 bicycle computer (Cherry Creek Cyclery, Fosters Falls, VA,
USA) to determine daily running distance. All animals were provided with standard rat
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chow (Formulab 5008, Purina Mills, St. Louis, MO) that consisted of approximately 26%
protein, 18% fat and 56% carbohydrates. Sedentary and WR groups had ad libitum access
to food. Body weights and food intakes were recorded on a weekly basis. At 20 weeks of
age, the rats were sacrificed and anesthetized using intraperiotneal injection of
pentobarbital sodium (50 mg/kg). Tissues were harvested after the animals were
euthanatized by exsanguination in full compliance to American Veterinary Medical
Association Guidelines on Euthanasia. Hearts were frozen and stored at -80oC until
analysis. The wheels of the WR group were locked and food was removed from the cages
of all groups approximately 14 hours before the rats were sacrificed (Crissey et al., 2014).

3.1.3 Gene Expression/RNA Extraction
RNA was extracted from frozen cardiac tissue and homogenized using TRIzol
reagent. The isolated RNA was then quantified using the Nanodrop 1000
spectrophotometer and used to make 0.2 ug of cDNA using 5X iScript (BioRad). The
primers used for the gene expression were designed and purchased from IDT. These
primers were optimized using EvaSsofast (BioRad) to an efficiency of >90%. All gene
expression analyses were ran in triplicate on the CFX96 RT-PCR machine with Rpl10a
serving as control gene. 18S was originally tested as a house-keeping gene but was found
to be expressed differently between our groups in the heart (figure 1A). We have found
that Rpl10a is a suitable house-keeping/reference gene when performing RT-PCR with
rat myocardium as it remains stable under the experimental conditions for these animals.
mRNA expression values were analyzed via the ΔCT method whereby ΔCT = Rpl10a CT
- gene of interest CT (Padilla et al., 2013). mRNA levels are normalized to the SED
group of rats, which was always set at 1 (Chrissy et al., 2014; Brattlelid et al., 2010).
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The genes that will be analyzed to determine cardiac dysfunction include: ANP, BNP, βMHC, and α-MHC in OLETF rats. ANP, BNP,β-MHC and α-MHC are members of the
fetal gene program and their re-emergence in adult cardiac gene expression represents a
pathological sign of cardiac dysfunction. CD4, a general T-cell marker is used to identify
potential immune cell infiltration and genetic expression in the heart. CD68, a general
marker of macrophages, was also used for this similar task. F4/80 is a marker for M1
polarized macrophages that are involved in secreting pro-inflammatory biomarkers.
COL1, COL3, and TGFβ1 are genes involved in the development of cardiac fibrosis.
Lastly, MCP-1 IL-1β and TNF-α are genes involved in pro-inflammation and are known
to have an effect in NF-κB activity. Rpl10a (F:5’-GAGGCGCATCTGATCCTAATC-3’,
R:5‘-ATTTCTGCCCGCTGTCTATC-3’) was used as the reference gene for RT-PCR.
The full name and primers for the genes used are listed in table 1. Tables 2-4 include the
genes that were studied, including primer sequences, as markers for inflammation,
inflammatory cell infiltration, and fibrosis.

Table 1. Names of Genes involved in Fetal Gene Programming
Gene Name

Full Name

ANP

Atrial Natriuretic Peptide

BNP

Beta (Brain) Natriuretic
Peptide

F: CCCTTGGTTTGCTCTCAGAC
R:AGGGGAGATGCTCAGAGTGA

α-MHC

Alpha Myosin Heavy
Chain

F: GCACTGAGGGGATAAGGTGA
R: TTAGCCCAACCCAAAGTGTC

β-MHC

Beta Myosin Heavy
Chain

F:ACAAACCATGACCAACAGCA
R: GGCTGTGGGGTTACTTCAGA
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F (Forward) & R (Reverse) Primer
sequence (5’-3’ direction)
F: TGCCGGTAGAAGATGAGGTC
R: AGCCCTCAGTTTGCTTTTCA

Table 2. Genes involved in inflammation
Gene Name

Full Name

F (Forward) & R (Reverse) Primer
sequence (5’-3’ direction)

MCP-1

Macrophage Chemoattractant Protein-1

F:AGCTGGGCATGACTGACATCT
R:AGCCGACTCATTGGGATCAT

IL-1β

Interleukin 1β

F:GACCTGTTCTTTGAGGCTGACA
R:CTCATCTGGACAGCCCAAGTC

TNF-α

Tumor Necrosis Factoralpha

F: AACACACGAGACGCTGAAGT
R: TCCAGTGAGTTCCGAAAGCC

Table 3. Genes involved with Fibrosis
Gene Name

Full Name

F (Forward) & R (Reverse) Primer sequence (5’-3’
direction)

COL1

Collagen Type 1

F:CTCTTTTAGGGACCCCAAGG
R:GCTCCTCTCCCACTATGCAG

COL3

Collagen Type 3-α

F:GGGATCCAATGAGGGAGAAT
R:TCCTGCTTCCAATCGACTTT

TGF-β1

Transforming
Growth Factor β1

F: AAAGAATTCGGGGTTCGCGCTCTCCGAAG
R:AAACTCGAGTTATCAGCTGCACTTGCAGGAG

Table 4. Genes involved with monocytes and macrophages
Gene Name

Full Name

F (Forward) & R (Reverse) Primer
sequence (5’-3’ direction)

CD4

Cluster of Differentiation 4

F: ACCCTAAGGTCTCTGACCCC
R: TAGGCTGTGCGTGGAGAAAG

CD68

Cluster of Differentiation 68

F:CTTGGCTCTCTCATTCCCTTAC
R:CTGGTAGGTTGATTGTCGTCTC

F4/80

EGF-like module-containing
mucin-like hormone receptorlike
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F: GCCATAGCCACCTTCCTGTT
R: ATAGCGCAAGCTGTCTGGTT

3.1.4 NF-κB ELISA Assay
NF-κB analyses were performed on all three groups: caloric restriction (CR),
wheel running (WR) and sedentary (SED) groups for a total of 30 subjects (n=10 in each
group). Nuclear extractions were prepared by homogenizing tissue samples using a
commercial nuclear extraction kit (Nuclear Extraction Kit, Active Motif) according to the
manufacturer’s instructions. Briefly, about 20-50 µg of frozen tissue was collected and
crushed. While on ice, the crushed tissue was placed in a pre-chilled Dounce
homogenizer and 400 µL of ice-cold 1X Hypotonic buffer containing phosphatase and
protease inhibitors supplemented with DTT and detergent was added. Then a largeclearance (A) pestle was used to disrupt tissue for about 2 minutes. The samples were
incubated for 15 minutes on ice and centrifuged for 10 minutes at 850 x g at 4°C. Next
the single cell slurry is subjected to a cell lysis protocol consisting of 200 µL 1X
Hypotonic buffer was added to the slurry and allowed 15 minute incubation on ice to
allow the cells to swell. 15 µL of detergent was then added and the cells were vortexed
for 10 seconds at the highest setting. The suspension is then centrifuge for 30 seconds at
14,000 x g in a microcentrifuge pre-cooled at 4°C. The supernatant was then transferred
off to pre-chilled tubes (this supernatant contains the cytoplasmic fractionation) and the
nuclear pellet is resuspended in 50 µL of Complete Lysis Buffer by pipetting up and
down. The suspension is then incubated for 30 minutes on ice on a rocking platform set at
150 rpm. Suspension was then vortexed for 30 seconds at the highest settings and
centrifuged for 10 minutes at 14,000 x g in a 4°C pre-chilled microcentrifuge. The
supernatant, containing the nuclear protein fraction, is pipetted off and stored at -80°C
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and quantified. Total nuclear protein content was determined using a BSA-based protein
quantification assay (ProStain; ActiveMotif, Carlsbad, CA, USA).
NF-κB activation was determined using the nuclear extracts, as described above,
and an ELISA-based Trans AM NF-κB p65 assay kit (ActiveMotif, Carlsbad, CA, USA)
according to the manufacturer’s directions. In short, 15 µg/µL of nuclear extract were
added to wells coated with a consensus binding sequence for NF-κB (5’GGGACTTTCC-3’) and incubated for 1 hour at room temperature. Wells were then
washed, and a primary antibody directed at the p65 subunit was added and left to
incubate for 1 hour. This is followed by treatment of all wells with a secondary antibody
conjugated to horseradish peroxidase. A subsequent colorimetric reaction is initiated with
the addition of a developing solution for 5 min followed by the application of a stop
solution. The absorbance of the plate is then read at 450 nm on a multiwall microplate
reader (FLUOstar Optima, BMG Labtech, Offenburg, Germany). Wild-type and mutated
consensus oligonucleotides were used as competitors for NF-κB binding to ensure
specificity of the reaction as per the manufacturer’s instructions. All samples were run in
duplicate, and the average value used for data analysis (LaBarbera et al., 2015; Hyldahl et
al., 2011).

3.2 Preliminary Data
Data has been published previously on this cohort of animals by Crissey, et al
(2014). Figure 1 represents the OLETF rat characteristics at 5 weeks and at the end of 20
weeks when the animals were sacrificed. Changes in body composition in WR and CR
groups were significant compared to the sedentary group, exhibiting lower percent body
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fat and less visceral adipose tissue mass. Food intake increased from five weeks for all
animal groups. The caloric restriction and sedentary group exhibited no changes in food
intake after 12 weeks during the intervention period. The wheel running group exhibited
fluctuations in food intake, with a decrease occurring around 14 weeks, which may be
due to exercise effects. The relative food intake was approximately the same for all
groups until during the intervention phase, where the WR group exhibited an increase
relative to body weight. In addition, heart weight for both WR and CR were significantly
different compared to the SED group. Heart weight to body weight ratio (HW/BW) was
significantly different in the WR compared to SED while CR HW/BW ratio was
significantly different compared to WR. Lastly, percent body fat for the WR was
significantly different from the SED group and CR percent body fat was significantly
different from the WR group.
As summarized in table 5 (table 4 from Crissey et al., 2014) and described above,
compared to the sedentary group, WR and CR plasma had lower triglycerides, total
fasting cholesterol, LDL cholesterol, NEFAs, glucose and leptin. Lastly, the WR group
exhibited improvements in HOMA-IR, lower plasma insulin and lower circulating MCP1 compared with sedentary rats (P< 0.05) (Crissey et al., 2014). Fasting plasma levels of
IL-6, a marker of inflammation, were not different between SED, WR, and CR. However,
TNF-α fasting plasma levels was statistically different between WR and CR (P< 0.05),
with CR exhibiting higher fasting plasma level of TNF-α. Overall, the data from Crissey
et al. shows that exercise and a 30% diet restriction regimen for 8 weeks was related to
reduced adiposity, improved blood lipid profiles and systemic markers of insulin
resistance in 20-week-old obese OLETF rats.
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CHAPTER 4
RESULTS
4.1 Reference Gene Quality Control
18S and RPL10a were evaluated for their appropriateness as control gene for RTPCR. Figure 1A and 1B show the average Ct values of 18S and RPL10a, respectively. 1way ANOVA revealed that18S Ct values were significantly different between groups.
Post-hoc analysis showed that there were significant differences between CR vs. SED
and CR vs. WR (p<0.001) but no differences between SED vs. WR. RPL10a Ct values
showed no difference between groups as depicted in figure 1B and was therefore used as
the reference gene for all RT-PCR gene expression analyses.
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Figure 1. Ct values of RPL10a and 18S mRNA expression in cardiac
tissue from caloric restriction (CR), wheel running (WR), and
sedentary (SED) groups. (A) 18S Ct values from the means of 10
different runs. (B) Rpl10a Ct values from one run. Values are
expressed as means ± SE (n=10/group). * Denotes difference (p<0.05)
from SED; † Denotes difference (p<0.05) from WR.

4.1.2 Cardiac Dysfunction: Fetal Gene Expression and Fibrosis
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To assess cardiac dysfunction in heart tissue of OLETF rats, we examined the
pattern of α-MHC, β-MHC, ANP, BNP, TGFβ-1, collagen 1, and collagen 3 mRNA
expression in the three different conditions (CR, WR, and SED). As shown in Fig. 2,
there were no significant differences between groups in the mRNA expression of genes
involved in the fetal gene program and in fibrosis; Fig. 2A, α-MHC (p=0.385); Fig. 2B,
β-MHC (p=0.63); Fig. 2C, ANP (p=0.56); Fig. 2D, BNP (p=0.857); Fig. 2E, TGFβ1
(p=0.323); Fig. 2F, COL1 (p=0.9), and Fig. 2G, COL3 (p=0.581).
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Figure 2. Expression of genes related to cardiac dysfunction in caloric
restriction (CR), wheel running (WR), and sedentary (SED) groups. αMHC (A), β-MHC (B), ANP (C), BNP (D), TGFβ-1 (E), Collagen 1 (F), and
Collagen 3 (G) mRNA expression was measured by RT-PCR. Values are
expressed as means ± SE (n=10/group). For each gene, SED is used as the
reference group and set at 1.
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4.1.3 NF-κB Activation in Cardiac Tissue of OLETF rats
Nuclear extractions were performed on the cardiac tissue of OLETF rats in the
WR, CR, and SED groups and used to determine p65 NF-κB activity. Figure 3 shows the
values for the NF-κB activity of the WR, CR, and SED groups. There were no significant
differences in NF-kB activity between groups. 1-way ANOVA showed that there was a
trend for an overall effect of group (p=0.07) on NF-κB activation, with CR exhibiting
greater NF-κB activation compared to SED (P=0.06).
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Figure 3. NF-κB activation in cardiac tissue in caloric
restriction (CR), wheel running (WR), and sedentary (SED)
groups. Values are expressed as means ± SE (n=10/group).

4.1.4 Markers of Immune Cells and NF-κB activity
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We examined the pattern for CD4, CD68, F4/80, MCP-1, TNF-α, and IL-1β
mRNA expression in cardiac tissue of the CR, WR, and SED groups. As shown in Fig. 4,
there were no differences in the mRNA levels of immune cell and NF-κB related target
genes in the three different groups. Fig. 4A, CD4 (p=0.436); Fig. 4B, CD68 (p=0.402);
Fig. 4C, F4/80 (p=0.603); Fig. 4D, MCP-1 (p=0.649); Fig. 4E, IL-1β (0.188) and Fig. 4F,
TNF-α (p=0.745).
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Figure 4. Expression of immune cell related and pro-inflammatory NF-κB genes
of caloric restriction (CR), wheel running (WR), and sedentary (SED). (A) mRNA
expression of CD4. (B) mRNA expression of CD68. (C) F4/80 mRNA expression. (D)
MCP-1 mRNA expression. (E) IL-1β mRNA expression. (F) TNF-α mRNA
expression. Values are expressed as means ± SE (n=10/group). For each gene, SED is
used as the reference group and set at 1.
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CHAPTER 5
DISCUSSION
In this study, we aimed to determine effects of WR and CR to reduce markers of
cardiac dysfunction, NF-κB activity, and gene expression related to NF-κB and immune
cell infiltration compared with SED controls in 20 week old OLETF rats. Our major
findings were: 1) there were no significant differences in markers of cardiac dysfunction
between the groups, 2) there was a trend for increased NF-κB activity in the CR
compared to the SED group and 3) there were no significant differences in the gene
expression of markers related to immune cell infiltration and NF-κB target genes in the
20 week old OLETF rats.
Our data on cardiac dysfunction in OLETF rats complements and extends that of
Yagi and colleagues (1997) in which cardiac dysfunction of OLETF rats were
characterized over 54 weeks. In this study, investigators examined pathological features
of the heart and markers of cardiac complications in OLETF rats from the pre-diabetic
state (14 weeks), non-insulin dependent diabetes mellitus (30 weeks) and insulin
dependent diabetes mellitus (54 weeks), evaluating fetal gene expression and genes
involved in cardiac fibrosis as markers for changes in cardiac performance. In addition,
the Long-Evans Tokushima-Otsuka (LETO) rats were evaluated as the genetic control
animals for the OLETF rats. The researchers found that there were no differences in fetal
gene expression markers in OLETF rats between 14 weeks, at 30 weeks and that while a
small difference in β-MHC was observed between OLETF and LETO at 30 weeks, larger
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differences between OLETF and LETO in α-MHC, β-MHC, and ANP expression were
only observed at 54 weeks. This data indicates that changes in cardiac fetal gene
program expression do not appear until later in the OLETF model. Therefore, although
we did not have a LETO group for comparison, it is possible that we did not observe any
differences between the groups because they were only 20 weeks old, which would not
be long enough for SED animals to develop a fetal gene signature. Further, fetal gene
expression should not change with exercise, as it is not activated in normal physiological
hypertrophy (Maillet et al., 2013). To our knowledge, there are no studies that have
investigated the effects of CR on the fetal gene program. However, since CR is known to
attenuate insulin sensitivity in the heart of OLETF rats (Park et al., 2005) and improve
cardiac energy metabolism (Dolinsky et al., 2010; Kemi et al., 2000), we would not
anticipate that CR would also help maintain proper cardiac function and prevent an
emergence of the fetal gene program.
Interestingly, according to data from the same study (Yagi et al., 1997), there is
evidence that cardiac fibrosis occurs at early time points in the OLETF model and that it
may be related to inflammation. Investigators reported that at 14 weeks of age, the left
ventricular gene expression of collagen types I, III and IV, along with laminin, were
significantly enhanced in OLETF compared with LETO rats of the same age. Collagen
types III and IV and laminin mRNA levels remained elevated in OLETF rats at week 30
compared to LETO. Transforming Growth Factor-β (TGF-β) is a pleiotropic cytokine
that can regulate fibrogenesis and is released from pro-inflammatory cells (e.g.
macrophages). The authors showed that mRNA levels of 14-, 30-, and 54-week-old
OLETF rats were 1.5-, 1.6-, and 1.3-fold greater, respectively, than in the LETO rats
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examined at those same time points. Thus, according to this study, markers of fibrosis are
evident at as early as 14 weeks in the OLETF model when animals are overweight and
insulin resistant. We expected that markers of fibrosis would be lower in EX and CR
groups compared with SED in our study in line with existing myocardial fibrosis
suspected at 20 weeks (Mizushige et al., 2000). Contrary to our hypothesis, we found no
differences between groups in markers of fibrosis. Since we do not have LETO control
animals as a comparison, it is unknown whether the fibrosis occurs in the OLETF heart
independent of CR and EX interventions.
Caloric restriction and exercise are known to induce pleiotropic forms of
cardiovascular protection (Dolinsky and Dyck, 2011; Shinmura et al., 2010). CR is able
to increase longevity and reduce death due to chronic diseases such as cancer, T2DM,
obesity, and cardiovascular disease. Indeed, research has shown that CR is able to
attenuate the production of ROS and oxidative damage by activation of SIRT1 and
transcription factor NF-E2-related factor (Nrf2) (Csiszar et al., 2009). In addition, CR is
able to attenuate age-related vascular inflammation by improving the NF-κB inhibition of
pro-inflammatory gene transcription, thereby causing NF-κB to become active in antiinflammatory gene transcription and reducing a pro-inflammatory state (Weiss &
Fontana, 2011). Lastly, like exercise, CR is able to reduce adiposity and inflammatory
markers, especially in the cardiovascular system, leading to healthy cardiovascular
function and can even decrease the adverse effects of cardiomyopathy (Weiss & Fontana,
2011; Kemi et al., 2000).
We hypothesized that the inhibitory effect of CR and EX on overall systemic
inflammation in OLETF rats would be reflected in the heart and mediated through
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inhibition of NF-κB’s pro-inflammatory factor transcription (Medeiros et al., 2011).
Adiposity, especially in obesity and diabetes, exhibits paracrine and autocrine signaling
of pro-inflammatory markers, thus leading to greater NF-κB activity and mRNA
expression of pro-inflammatory markers in adipose tissue (Romacho et al., 2014). In the
study conducted by Crissey and colleagues (2014), which analyzed the same animals as
the present study, WR and CR in 20-week old OLETF rats showed lower gains in body
weight over time, lower adipose tissue mass, and lower adipose tissue expression of
inflammatory genes and markers of immune cell infiltration compared to the SED group.
Furthermore, in periaortic adipose and aortic tissue, they reported lower expression of
cytokines in WR and CR compared with SED. Contrary to our second hypothesis our
data showed a trend for increased NF-kB activity in CR compared with SED. We also
witnessed that there were no significant differences in the gene expression of markers
related to immune cell infiltration and NF-κB target genes in the heart of these 20 week
old OLETF rats, providing evidence that inflammation may not play a role in the heart at
this time point.
The literature has focused mainly on the pro-inflammatory side of NF-κB and
there is still a lack of information on the role of NF-κB on cardioprotection and antiinflammation in the heart. It is possible that our results could reflect the antiinflammatory and anti-apoptotic activity of NF-κB, though more research is needed. It
has been shown that the anti-apoptotic activity of NF-κB depends on certain gene
induction (Lui et al., 1996). NF-κB can induce the expression of cellular inhibitors of
apoptosis (c-IAPs), caspase-8-c-FLIP (FLICE inhibitory protein), Bfl1, TNFR-associated
factor (TRAF1) and TRAF2. TRAF1 and TRAF2 are adaptor proteins required in
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optimizing NF-κB activity and it is postulated that their anti-apoptotic activity is most
likely due to their ability in augmenting the activation of NF-κB (Karin & Lin, 2001).
The c-IAPs proteins can directly bind and inhibit effector caspases, such as caspase-3 and
caspase-7, and prevent activation of pro-caspase-6 and pro-caspase-9 (Deveraux et al.,
1998). These c-IAPs can thus inhibit apoptosis induced by both death receptors and
mitochondria-dependent pathways. In particular, c-IAP1 and c-IAP2 expression by NFκB suppresses TNF-α mediated killing through inhibition of caspase-8 (Wang et al.,
1998).
There is data to suggest that NF-κB also inhibits apoptosis by DNA damaging
agent, which act via the mitochondria-dependent pathway (Baldwin, A.S., 2001). This
activity could be mediated through members of the Bcl-2 family, a family of pro- and
anti-apoptotic proteins situated in the mitochondria, such as Bcl-χL and Bfl1. It appears
that Bfl1 is able to induce its anti-apoptotic by preventing mitochondrial depolarization,
the release of cytochrome c and caspase-9 activation (Wang et al., 1999). In addition, it is
possible that Bcl-2 itself may be involved in the anti-apoptotic activity of NF-κB, as it is
defective in cells that lack both c-Rel and RelA (p65), the major activating subunits of
NF-κB (Grossman et al., 2000). However, more work is required to elucidate these
proteins and their pathways in relations to the heart as these pathways have been studied
most extensively in immune cells and oncogenesis.
Lastly, this study aimed to determine the comparative effectiveness of exercise
and caloric restriction on inflammation and cardiac NF-κB signaling in 20 week old
OLETF rats. From our results, it is difficult to state which of these two treatments is more
effective in reducing inflammation and cardiac NF-κB activity. Data from Crissey et al.,
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shows that exercise is more effective in reducing fasting plasma levels of MCP-1, TNF-α,
and other markers of obesity and diabetes (Crissey et al., 2014). In this regard, exercise is
more effective than caloric restriction in attenuating the effects of inflammation and
cardiometabolic syndrome parameters. Both caloric restriction and exercise have
important roles in reducing inflammation, improving longevity, and reducing the risk for
a multitude of diseases. In order to guide public health recommendations, more research
is needed to determine which intervention is more effective in early progression of
diseases such as diabetes and obesity. Further, there is much debate on the effects of NFκB activity in relation to cardiovascular disease and function that warrants further
investigation (Gordon et al., 2011).

5.1 Limitations and Future Studies:
A major limitation of this current study was the absence of tissue from LETO control
animals for analysis. Since the OLETF rat is a genetic model of T2DM and mild obesity,
a proper genetic control is needed to investigate and properly compare the effects of
interventions such as caloric restriction, sedentary behavior, and exercise. Future studies
require incorporation of LETO animals as a control group. Second, investigating the
changes in the heart at different time points, 14 weeks and 30 weeks, can help provide a
more complete picture of the effects of pre-diabetes on the hearts of OLETF rats. The
literature has witnessed differences at 14 weeks and 30 weeks though there exists limited
knowledge on WR and CR at these time periods. Lastly, our analysis of NF-κB activity
only provides information on the activation of NF-κB but warrants no information on
what regions of DNA it is binding to. In future studies, NF-κB binding should be
assessed using chromatin immunoprecipation (chIP) to determine what consensus
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binding regions are being transcribed by NF-κB. Furthermore, microarray analysis on
anti-inflammatory genes in cardiac tissues under the different interventions are warranted
to see if there is a connection between NF-κB activity and these anti-inflammatory
markers.
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